PD-1 Inhibitors Make Impact in Merkel Cell Carcinoma, But Unmet Needs Persist
Despite recent developments in the treatment landscape of Merkel cell carcinoma (MCC), including the 2023 FDA accelerated approval of the PD-1 inhibitor retifanlimab-dlwr (Zynyz), patients with the disease have a poor prognosis and have historically been …